Strategy EVOLVE+ paves the way for continued profitable growth

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), holds its Capital Markets Day today at its site in Barberà del Vallès near Barcelona. At this event, Marcel Imwinkelried, CEO since September 1, 2024, and CFO Reto Suter will provide deeper insight into Siegfried’s updated strategy. The strategy EVOLVE⁺ is set to further strengthen Siegfried’s position as a leading global integrated provider of development and manufacturing services. It builds on the cornerstones of the EVOLVE strategy which has enabled Siegfried to grow successfully and increase profitability in recent years.  

The most important fields of action of EVOLVE⁺ are: 

• Expand Siegfried’s core business and grow new areas to further develop the scale and strengths of the global network 

• Broaden the range of technologies and services, further enhancing Siegfried’s customer offering from early phase to commercial production 

• Sharpen focus on commercial, development, and operational excellence to accelerate profitable growth  

• Continue value accretive M&A as a catalyst to drive growth on all levels 

With EVOLVE⁺, Siegfried will successfully continue its growth trajectory, be an attractive employer for industry talents and create value for shareholders. The company’s medium-term financial targets remain unchanged. Siegfried expects to grow at or above market (excluding M&A), while further expanding its profitability. 

Marcel Imwinkelried, CEO: “The CDMO market continues to be very attractive and offers a uniquely positioned company like Siegfried attractive growth opportunities. Our position as a leading integrated supplier to the pharmaceutical industry makes us an important partner for our customers. By adapting our go-to-market strategy and by offering industry-leading development services at all clinical stages, we will be even more relevant to them. I am convinced that this will enable us to expand, to realize our full potential and to continue our successful growth path.”  

Participants in the Capital Markets Day will also have the opportunity to experience technology showcases and visit the production site in Barberà del Vallès. 

Further information  

Join the webcast taking place on October 24, 2024, at 09:15 CET 

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3’700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statement